IL237041A0 - A medical preparation of rasagiline which is not released in the intestines - Google Patents

A medical preparation of rasagiline which is not released in the intestines

Info

Publication number
IL237041A0
IL237041A0 IL237041A IL23704115A IL237041A0 IL 237041 A0 IL237041 A0 IL 237041A0 IL 237041 A IL237041 A IL 237041A IL 23704115 A IL23704115 A IL 23704115A IL 237041 A0 IL237041 A0 IL 237041A0
Authority
IL
Israel
Prior art keywords
rasagiline
parenteral formulation
parenteral
formulation
Prior art date
Application number
IL237041A
Other languages
English (en)
Hebrew (he)
Inventor
Fitzer-Attas Cheryl
Blaugrund Eran
Rom E Eliaz
Aviva Gross
Adi Mayk
Original Assignee
Teva Pharma
Cheryl Fitzer Attas
Blaugrund Eran
Rom E Eliaz
Aviva Gross
Adi Mayk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Cheryl Fitzer Attas, Blaugrund Eran, Rom E Eliaz, Aviva Gross, Adi Mayk filed Critical Teva Pharma
Publication of IL237041A0 publication Critical patent/IL237041A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL237041A 2012-08-17 2015-02-01 A medical preparation of rasagiline which is not released in the intestines IL237041A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684530P 2012-08-17 2012-08-17
US201361775318P 2013-03-08 2013-03-08
PCT/US2013/055404 WO2014028868A1 (en) 2012-08-17 2013-08-16 Parenteral formulation of rasagiline

Publications (1)

Publication Number Publication Date
IL237041A0 true IL237041A0 (en) 2015-03-31

Family

ID=50100474

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237041A IL237041A0 (en) 2012-08-17 2015-02-01 A medical preparation of rasagiline which is not released in the intestines

Country Status (10)

Country Link
US (1) US9308182B2 (enExample)
EP (1) EP2884972A4 (enExample)
JP (1) JP2015529196A (enExample)
AR (1) AR092168A1 (enExample)
BR (1) BR112015003451A2 (enExample)
CA (1) CA2882072A1 (enExample)
IL (1) IL237041A0 (enExample)
MX (1) MX2015002062A (enExample)
TW (1) TW201412304A (enExample)
WO (1) WO2014028868A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
HK1200314A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceuticals Usa, Inc. R(+)-n-methyl-propargyl-aminoindan
WO2014141280A1 (en) * 2013-03-13 2014-09-18 Abital Pharma Pipelines Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
WO1999061066A2 (en) * 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US6670378B2 (en) * 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
HUP0501084A2 (en) * 2005-11-23 2008-05-28 Richter Gedeon Nyrt New pharmaceutical compositions of high effectivity
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
RS52183B (sr) 2006-12-14 2012-10-31 Teva Pharmaceutical Industries, Ltd. Kristalna čvrsta baza razagilina
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009089049A1 (en) 2008-01-11 2009-07-16 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations, their preparation and use
US20100008983A1 (en) 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
AU2010304755A1 (en) 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
CN102791258B (zh) * 2010-02-03 2018-05-08 图必制药公司 雷沙吉兰的延长释放制剂及其用途
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
MX2013004598A (es) 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
JP2014534195A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
HK1200314A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceuticals Usa, Inc. R(+)-n-methyl-propargyl-aminoindan
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan

Also Published As

Publication number Publication date
WO2014028868A1 (en) 2014-02-20
JP2015529196A (ja) 2015-10-05
US9308182B2 (en) 2016-04-12
TW201412304A (zh) 2014-04-01
US20140051767A1 (en) 2014-02-20
EP2884972A1 (en) 2015-06-24
CA2882072A1 (en) 2014-02-20
AR092168A1 (es) 2015-03-25
MX2015002062A (es) 2015-06-05
BR112015003451A2 (pt) 2017-07-04
EP2884972A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
TWI560901B (en) Epitaxial structure
ZA201406082B (en) Use of ccr3-inhibitors
ZA201306000B (en) Stable formulation
PT2641941E (pt) Preparação de pigmentos
GB201420527D0 (en) Electrical-wire-protecting member
SI2925338T1 (sl) Liofilizirana formulacija TAT-NR2B9C
GB201903206D0 (en) n
SG11201504134SA (en) External preparation
EP2756388A4 (en) PRESENTATION OF DEVICES IN THE FORM OF APPLICATIONS
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL2701506T3 (pl) Składnik formulacji
GB2518076B (en) Electrical-wire-protecting member
GB201121377D0 (en) Formulation component
GB201220119D0 (en) Vector
EP2884972A4 (en) PARENTERAL FORMULATION OF RASAGILINE
GB201107039D0 (en) Formulation component
GB201205795D0 (en) Vector
ZA201408149B (en) Parenteral esmolol formulation
EP2807545A4 (en) DESKTOP EXTENSION
PL2668154T3 (pl) Składnik formulacji
GB201220556D0 (en) Sustained-release formulation
TWM433480U (en) Locking member
GB201211247D0 (en) Improved formulation
GB201210088D0 (en) Odontalgic preparation
TWM433525U (en) Structure of calorifier